Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sangamo Biosciences Inc Reiterates FY 2013 Revenue Guidance

Wednesday, 8 May 2013 04:02pm EDT 

Sangamo Biosciences Inc reiterated its fiscal 2013 guidance and expects revenues will be in the range of $20-$24 million , inclusive of research funding from Shire. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $20 million for fiscal 2013. 

Company Quote

-0.82 -6.27%
24 Jul 2014